Open Access

Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature

  • Authors:
    • Natalie Herold
    • Barbara Wappenschmidt
    • Birgid Markiefka
    • Katharina Keupp
    • Sandra Kröber
    • Eric Hahnen
    • Rita Schmutzler
    • Kerstin Rhiem
  • View Affiliations

  • Published online on: January 22, 2018     https://doi.org/10.3892/ol.2018.7836
  • Pages: 4093-4096
  • Copyright: © Herold et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Non-small cell neuroendocrine carcinomas (NSCNEC) account for 2% of gynecological cancer cases and are associated with a poor prognosis due to delayed diagnosis and aggressive tumor behavior. BRCA2‑associated ovarian carcinomas predominantly possess a high‑grade serous phenotype, which respond to platinum and targeted therapy with PARP inhibitors. Presented here is the case of an adult patient with NSCNEC of the ovaries associated with a deleterious BRCA2 germline mutation. The pathogenic mutation was also confirmed on the somatic level, while the wild‑type allele had a high variant fraction, suggesting loss of heterozygosity. To the best of our knowledge, this is the first report of an adult BRCA2 germline mutation carrier with the rare NSCNEC of the ovary phenotype. Therefore, ovarian cancer patients with histological subtypes other than high‑grade serous carcinomas should be tested for BRCA1/2 mutations, as they may benefit from targeted therapy with poly (ADP-ribose) polymerase inhibitors.

References

1 

Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 265:2088–2090. 1994. View Article : Google Scholar : PubMed/NCBI

2 

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet. 72:1117–1130. 2003. View Article : Google Scholar : PubMed/NCBI

3 

Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P, Klijn JG, et al: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 10:2473–2481. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Soegaard M, Kjær SK, Cox M, Wozniak E, Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA and Ramus SJ: BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from denmark. Clin Cancer Res. 14:3761–3767. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E and Sadetzki S: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J Clin Oncol. 26:20–25. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA and Karlan BY: Improved survival in women with BRCA associated ovarian carcinoma. Cancer. 97:2187–2195. 2003. View Article : Google Scholar : PubMed/NCBI

7 

Moynahan ME, Chiu JW, Koller BH and Jasin M: BRCA1 controls homology-directed DNA repair. Mol Cell. 4:511–518. 1999. View Article : Google Scholar : PubMed/NCBI

8 

Moynahan ME, Pierce AJ and Jasin M: BRCA2 Is required for homology-directed repair of chromosomal breaks. Mol Cell. 7:263–272. 2001. View Article : Google Scholar : PubMed/NCBI

9 

Bolton KL, Chevenvix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, et al: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 307:382–390. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361:123–134. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet. 376:245–251. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Nijman SM: Synthetic lethality: General principles, utility and detection using genetic screens in human cells. FEBS Lett. 585:1–6. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Rouzbahman M and Clarke B: Neuroendocrine tumors of the gynecologic tract: Select topics. Semin Diagn Pathol. 30:224–233. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Gardner GJ, Reidy-Lagunes D and Gehrig PA: Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol. 122:190–198. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Taube ET, Denkert C, Pietzner K, Dietel M, Sehouli J and Darb-Esfahani S: Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma. Virchows Arch. 466:333–342. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Bhatla T, Dandekar S, Lu BY, Wang J, Han E, Bitterman D, Jones CL, Evensen NA, Magid M, Meyer JA and Carroll WL: Genomic characterization of poorly differentiated neuroendocrine carcinoma in a pediatric patient. J Pediatr Hematol Oncol. 38:e21–e25. 2016. View Article : Google Scholar : PubMed/NCBI

17 

Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, du Bois A, Petru E, Meier W, Ortner P, König K, et al: S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumors: Short version 1.0-AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd. 73:874–889. 2013.PubMed/NCBI

18 

Prat J; FIGO Committee on Gynecologic Oncology, : FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication. J Gynecol Oncol. 26:87–89. 2015. View Article : Google Scholar : PubMed/NCBI

19 

National Comprehensive Cancer Network, . NCCN Clinical Practise Guidelines in Oncology: (NCCN) Ovarian cvancer including fallopian tube cancer and primary peritoneal cancer. Version 1. 2015.

20 

Meindl A, Ditsch N, Kast K, Rhiem K and Schmutzler RK: Hereditary breast and ovarian cancer: New genes, new treatments, new concepts. Dtsch Arztebl Int. 108:323–330. 2011.PubMed/NCBI

21 

Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Sprudle AB and Tavtigian SV and Tavtigian SV; IARC Unclassified Genetic Variants Working Group, : Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 29:1282–1291. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, et al: Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 372:2243–2257. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Herold, N., Wappenschmidt, B., Markiefka, B., Keupp, K., Kröber, S., Hahnen, E. ... Rhiem, K. (2018). Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature. Oncology Letters, 15, 4093-4096. https://doi.org/10.3892/ol.2018.7836
MLA
Herold, N., Wappenschmidt, B., Markiefka, B., Keupp, K., Kröber, S., Hahnen, E., Schmutzler, R., Rhiem, K."Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature". Oncology Letters 15.4 (2018): 4093-4096.
Chicago
Herold, N., Wappenschmidt, B., Markiefka, B., Keupp, K., Kröber, S., Hahnen, E., Schmutzler, R., Rhiem, K."Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature". Oncology Letters 15, no. 4 (2018): 4093-4096. https://doi.org/10.3892/ol.2018.7836